Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

被引:33
|
作者
Bolte, Laura A. [1 ,2 ,3 ]
Lee, Karla A. [4 ]
Bjork, Johannes R. [1 ,2 ,3 ]
Leeming, Emily R. [4 ]
Campmans-Kuijpers, Marjo J. E. [1 ,2 ]
de Haan, Jacco J. [1 ,2 ,5 ]
Vila, Arnau Vich [1 ,2 ,3 ]
Maltez-Thomas, Andrew [6 ]
Segata, Nicola [6 ,7 ]
Board, Ruth [8 ]
Harries, Mark [9 ]
Lorigan, Paul [10 ]
de Vries, Elisabeth G. E. [2 ,5 ]
Nathan, Paul [11 ]
Fehrmann, Rudolf [2 ,5 ]
Bataille, Veronique [4 ,12 ]
Spector, Tim D. [4 ]
Hospers, Geke A. P. [2 ,5 ]
Weersma, Rinse K. [1 ,2 ]
机构
[1] Univ Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Groningen, Dept Genet, Groningen, Netherlands
[4] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England
[5] Univ Groningen, Dept Med Oncol, Groningen, Netherlands
[6] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy
[7] European Inst Oncol, IRCSS, Milan, Italy
[8] Lancashire Natl Hlth Serv NHS Fdn Trust, Royal Preston Hosp, Dept Med Oncol, Fulwood, England
[9] Guys & St Thomass NHS Trust, Guys Canc Ctr, Dept Med Oncol, London, England
[10] Christie NHS Fdn Trust, Dept Dermatol, Manchester, England
[11] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, England
[12] West Hertfordshire NHS Trust, Dept Dermatol, Watford, England
关键词
IMMUNOTHERAPY; QUALITY; CANCER;
D O I
10.1001/jamaoncol.2022.7753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, isa poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB.OBJECTIVE To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021.EXPOSURES Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment.MAIN OUTCOMES AND MEASURES Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher.RESULTS There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54).CONCLUSIONS AND RELEVANCE This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.
引用
收藏
页码:705 / 709
页数:5
相关论文
共 50 条
  • [21] Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade
    Aditya Jain
    Shijia Zhang
    Ryan M. Shanley
    Naomi Fujioka
    Robert A. Kratzke
    Manish R. Patel
    Amit A. Kulkarni
    Cancer Immunology, Immunotherapy, 2023, 72 : 1225 - 1232
  • [22] Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
    Spain, Lavinia
    Larkin, James
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 389 - 396
  • [23] Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade
    Jain, Aditya
    Zhang, Shijia
    Shanley, Ryan M.
    Fujioka, Naomi
    Kratzke, Robert A.
    Patel, Manish R.
    Kulkarni, Amit A.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (05) : 1225 - 1232
  • [24] Systematic association analysis of immune checkpoint blockade of PD-1 by RNA-seq data in advanced melanoma patients
    Wang, Shu
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
    Le, H. M. L.
    Pozas Perez, J.
    San Roman Gil, M. V.
    Serrano Domingo, J. J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S691 - S691
  • [26] COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma
    Arenbergerova, M.
    Gkalpakiotis, S.
    Arenberger, P.
    Fialova, A.
    Pasek, M.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1782 - 1783
  • [27] Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
    Rogiers, Anne
    Boekhout, Annelies
    Schwarze, Julia K.
    Awada, Gil
    Blank, Christian U.
    Neyns, Bart
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [28] EVOLUTION OF HLA HAPLOTYPE LOSS IN MELANOMA PATIENTS AND ITS ASSOCIATION WITH RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE
    Zhao, Fang
    Schwamborn, Marion
    Thier, Beatrice
    Crivello, Pietro
    Heinold, Andreas
    Ahci-Hanci, Mueberra
    Meurer, Thuja
    Lennerz, Volker
    Sucker, Antje
    Griewank, Klaus
    Horn, Peter A.
    Ugurel, Selma
    Woelfel, Thomas
    Fleischhauer, Katharina
    Schadendorf, Dirk
    Paschen, Annette
    HLA, 2019, 93 (05) : 273 - 273
  • [29] A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
    van Not, Olivier J.
    Wind, Thijs T.
    Ismail, Rawa K.
    Bhattacharya, Arkajyoti
    Jalving, Mathilde
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    Boers-Sonderen, Marye J.
    van den Eertwegh, Alfonsus J. M.
    de Groot, Jan Willem B.
    Haanen, John B.
    Kapiteijn, Ellen
    Bloem, Manja
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Stevense-den Boer, Marion
    van der Veldt, Astrid A. M.
    Vreugdenhil, Gerard
    Wouters, Michel W. J. M.
    Blokx, Willeke A. M.
    Suijkerbuijk, Karijn P. M.
    Fehrmann, Rudolf S. N.
    Hospers, Geke A. P.
    CANCERS, 2023, 15 (11)
  • [30] The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
    Zaremba, Anne
    Eggermont, Alexander M. M.
    Robert, Caroline
    Dummer, Reinhardt
    Ugurel, Selma
    Livingstone, Elisabeth
    Ascierto, Paolo A.
    Long, Georgina, V
    Schadendorf, Dirk
    Zimmer, Lisa
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 268 - 280